FDA to Develop Patient-Focused Drug Development Guidance

News
Article

FDA announced it is developing a series of guidance documents to promote methodological patient-focused drug development.

On Sept. 3, 2019, FDA announced that it will be developing a series of guidance documents as part of the agency’s patient-focused drug development efforts in accordance with the 21st Century Cures Act and The Food and Drug Administration Reauthorization Act of 2017 Title I.

There will be four guidance documents on methodological patient-focused drug development in the series, and they will address how stakeholders can collect and submit patient data and other relevant patient information for the development of medical products.

The first guidance, Collecting Comprehensive and Representative Input, will discuss sampling methods used when planning to collect patient input. Guidance number two, Methods to Identify What is Important to Patients, will discuss methods for eliciting information from patients identified in guidance one and gathering information on symptoms and impact on patients. The third guidance will address refining the list of important impacts and concepts to develop study instruments, and the fourth guidance will address methodologies, standards, and technologies for the collection, capture, storage, and analysis of clinical outcome assessment data.

“This series of guidance documents is intended to facilitate the advancement and use of systematic approaches to collect and use robust and meaningful patient and caregiver input that can better inform medical product development and regulatory decision making,” FDA said in the announcement.

Source: FDA

 

Recent Videos
Ian Lafferty from Upperton discusses the trends and challenges facing sterile manufacturing and how partnering with CDMOs can help innovators progress to the market.
Miguel Forte from ISCT and Kiji Therapeutics talks about the potential impact of a changing European political landscape.
Miguel Forte from ISCT and Kiji Therapeutics provides his insights into the changing political landscape in the US as well as legislative and regulatory adjustments
Miguel Forte from ISCT and Kiji Therapeutics chats about expectations for 2025 and the future technology agenda for industry.
Sheryl Johnson from Orbia Fluor & Energy Materials chats about gender diversity, how women are helping to advance innovation, sustainability challenges, and progress in the field of inhaled drugs.
Mike Baird from Schlafender Hase gives his predictions for how AI and ML may find use in the industry moving forwards and provides some predictions about M&A and the changing US government administration.
Mike Baird from Schlafender Haser discusses industry trends from 2024 and those expected to have an impact in 2025 from the perspective of a software developer.
Preeya Beczek from Beczek.COM gives her thoughts on the areas to watch with the new US administration and how Europe might be finalizing preparations for previous legislative changes
Related Content